MCL Literature Feed

The deubiquitinase USP35 stabilizes CXCR3 protein expression in MCL cells, promoting oncogenic signaling via JAK/STAT and c-Myc, identifying the USP35-CXCR3 axis as a novel therapeutic target.

This study developed and validated a new lymphoma-specific patient-reported outcome measure using the EORTC Item Library, providing a crucial tool for assessing MCL symptoms in clinical trials.

This 15-year real-world study benchmarks MCL survival outcomes, reflecting evolving treatment eras and providing crucial prognostic data from routine clinical practice.

Upregulation of the mTOR pathway drives acquired resistance to PRMT5 inhibitors in preclinical MCL models; combining with an mTOR inhibitor like temsirolimus overcomes this resistance and improves survival.

Pirtobrutinib, a non-covalent BTKi, gained FDA accelerated approval for MCL after prior BTKi failure, offering a 50% overall response rate for this high-unmet-need population.

This review summarizes the rare presentation of mantle cell lymphoma in the lacrimal sac, highlighting the unique diagnostic and multidisciplinary therapeutic challenges posed by this specific anatomical site.

Final overall survival data from a phase 2 trial confirm durable responses to acalabrutinib monotherapy in relapsed/refractory MCL, including in patients with poor prognostic features.

This pathology workshop report clarifies the differential diagnosis of aggressive B-cell lymphomas, including pleomorphic MCL, by applying updated WHO-HAEM5 and ICC 2022 classifications for improved diagnostic accuracy.

Radiation therapy is a feasible bridging strategy to control disease in relapsed/refractory MCL patients awaiting CAR-T infusion, potentially improving eligibility and outcomes for those with bulky disease.

This review analyzes the regulatory challenges and decision-making complexities for ibrutinib in MCL, stemming from inconsistent results across different pivotal clinical trials.

This paper proposes using the estimand framework to standardize definitions of Duration of Response (DOR) and Time to Response (TTR), using an MCL case study to improve trial endpoint clarity.

This review summarizes the evolution of MCL treatment, focusing on BTK inhibitor efficacy, toxicity, and their role in enabling personalized therapeutic strategies based on patient and disease factors.

Pirtobrutinib, the first approved non-covalent BTKi, offers a crucial new therapy for relapsed/refractory MCL by overcoming resistance mechanisms, including C481 mutations, from prior covalent BTK inhibitors.

This indirect comparison of ZUMA-2 (brexucabtagene autoleucel) and SCHOLAR-2 (standard of care) demonstrates a substantial overall survival benefit for CAR-T therapy in relapsed/refractory MCL after BTKi failure.

The British Society for Haematology provides updated, evidence-based guidelines on MCL diagnosis, risk stratification, and treatment algorithms, standardizing care for UK patients.

This commentary highlights the new British Society for Haematology guidelines, offering updated, comprehensive recommendations for MCL diagnosis and management, including guidance for difficult-to-treat clinical scenarios.

Combining the MCL35 gene signature with s-MIPI and blastoid cytology powerfully risk-stratifies older, frontline MCL patients receiving bendamustine-rituximab, identifying a dismal prognosis subgroup.

This review synthesizes MCL's genomic heterogeneity with the evolving therapeutic landscape, focusing on novel agents like BTKi and CAR-T and strategies for overcoming resistance in relapsed/refractory disease.

Pirtobrutinib, a non-covalent BTKi, shows a 52% overall response rate in relapsed/refractory MCL, including in patients previously treated with covalent BTKi, offering a new therapeutic option.

A machine learning algorithm accurately classifies MCL versus other B-cell lymphomas using standard peripheral blood flow cytometry data, offering a tool to standardize and accelerate initial diagnosis.

Italian real-world data highlights the poor prognosis and significant unmet clinical needs for relapsed/refractory MCL patients following covalent BTKi failure, emphasizing the urgency for novel treatment strategies.

This dual-center retrospective analysis of 20 patients with blastoid MCL characterizes its clinical features and prognosis, adding to the limited evidence base for this aggressive subtype.

The novel antiviral ensitrelvir resolved persistent COVID-19 in a heavily pretreated MCL patient on ibrutinib, highlighting a potential strategy to manage infections that delay essential lymphoma therapy.

An MCL patient with B-cell depletion had persistent COVID-19 for over 112 days, diagnosed via lower respiratory sampling, highlighting a unique vulnerability and successful treatment with convalescent plasma.

A preclinical prostate cancer model shows Bortezomib resistance is driven by autophagy induction and reduced oxidative stress, suggesting potential combination strategies with autophagy inhibitors for MCL.

This case of blastoid MCL with aberrant CD10 expression highlights a rare immunophenotype, creating a diagnostic pitfall that can mimic other aggressive B-cell lymphomas.

This paper outlines strategies for improved collaboration between community oncologists and authorized centers to overcome logistical and educational barriers, ensuring timely referral and access to CAR-T therapy for MCL.

This review explores targeting tumor-associated macrophages within the MCL microenvironment as a novel immunotherapeutic strategy to enhance anti-tumor activity and potentially overcome drug resistance.

This retrospective study outlines real-world treatment patterns for MCL from a single private practice in Brazil, providing crucial data on management outside of traditional clinical trial or academic settings.

This review identifies the lncRNA LINK-A as an upregulated oncogene in MCL, presenting it as a potential biomarker and therapeutic target involved in oncogenic pathways and therapy resistance.